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Introduction
Every year, approximately 62 000 people with stroke and transient ischemic attack (TIA) are treated in Canadian hospitals (1) . The annual cost of stroke is approximately $3·6 billion, taking into account both health-care costs and lost economic output (2) . Moreover, it is estimated that for each symptomatic stroke, there are nine 'silent' strokes that result in subtle changes in cognitive function and processes (3) . The risk of recurrent stroke after a TIA is 10-20% within 90 days, and the risk is 'front-loaded' , with half of the strokes occurring in the first two-days following initial symptom onset (4) (5) (6) (7) . The seven-day risk of stroke following a TIA can be more than 30% in patients with multiple risk factors (8) . Timely initiation of secondary prevention medical therapy and carotid endarterectomy has been shown to significantly reduce the risk of major stroke after an initial TIA or nondisabling stroke.
The Canadian Stroke Best Practice Recommendations are intended to provide up-to-date evidence-based guidelines for the prevention and management of stroke, to promote optimal recovery and reintegration for people who have experienced stroke (patients, families and informal caregivers). The target audience for this guideline is all health-care professionals involved in the care of people with stroke across the continuum. The goals of disseminating and promoting implementation of these recommendations are to reduce practice variations in the care of stroke patients across geographic regions; reduce the gap between current knowledge and clinical practice; and improve patient outcomes. The Canadian Stroke Best Practice Recommendations are updated and released in seven modules every two-years: Stroke Prevention; Mood, Cognition and Fatigue; Hyperacute Stroke; Acute Stroke; Rehabilitation; Transitions; and Telestroke (9) .
Up-to-date and comprehensive Canadian Best Practice Recommendations for Stroke Care are freely available at www .strokebestpractices.ca (9) . This print publication summarizes the recommendations for Secondary Prevention of Stroke, including a summary of the methods for their development and the evidence grading scheme used. In addition, the Web site contains detailed rationales for the recommendations with supporting evidence, health systems implications, suggested performance measures, implementation resources (such as decision tools and templates for standing orders), summary of the evidence, and detailed tables of evidence. The reader is encouraged to visit the Web site for more details.
What's new in 2014
The updated Canadian Secondary Prevention of Stroke guidelines have a few notable changes from the previous edition. These guidelines focus on management of people who have already had an initial stroke or TIA. While we recognize the critical role of primary prevention strategies, these are considered out of scope for this particular module, and this update has been refined to focus on prevention of recurrent stroke and TIA. Triage of patients with TIA and minor stroke for evaluation for secondary prevention remains an important focus of these guidelines. In a previous revision we removed a recommendation to use the ABCD 2 score for triage evaluation of TIA patients, as the score has not validated well in real-world practice. In this 5th edition of the guidelines we emphasize that patients who present within 48 h of symptom onset with transient or persistent motor or speech symptoms need to be transported to the closest emergency department with capacity for advanced stroke care (section 1.1). We recommend brain and vascular imaging (of the intra-and extracranial vessels) to be completed urgently using computed tomography (CT)/CT angiography (CTA; section 1.3). Another addition to this version of the prevention guidelines is the recommendation that in patients with suspected cardioembolic stroke, should the initial electrocardiogram (ECG), Holter monitor or cardiac monitoring not identify atrial fibrillation, then prolonged cardiac monitoring should be included as part of the diagnostic process (sections 1.3 and 7.1). The importance of obtaining a routine echocardiogram has been de-emphasized (section 1.3).
Recommendations for secondary prevention of stroke should be implemented throughout the recovery phase, including during emergency department and acute inpatient care, inpatient and outpatient rehabilitation, reintegration into the community and ongoing follow-up by primary care practitioners. Secondary prevention should be addressed at all appropriate health-care encounters on an ongoing basis following a stroke or TIA. The health-care and stroke system should be set up to ensure secondary prevention is offered and maintained in all stages of stroke care. To help support ongoing stroke prevention monitoring and management, the global poststroke checklist has been adapted and modified and included as a helpful knowledge translation tool (9, 10) . The adapted Canadian version of the poststroke checklist is available online at www.strokebestpractices.ca (8) .
Guideline development methodology
The Canadian Stroke Best Practice Recommendations development and update process follows a rigorous framework adapted from the Practice Guideline Evaluation and Adaptation Cycle (11) . An interprofessional group of stroke prevention experts were convened to participate in reviewing, drafting, and revising all recommendation statements. Members who have extensive experience in the topic area, are considered leaders and experts in their field, have been involved in clinical trials or publications on the topics addressed in this module, and those who have experience appraising the quality of research evidence were selected. People who have experienced a stroke or their family members are also included as group members and/or external reviewers. The interprofessional writing group included stroke neurologists, family physicians, internists, nurses, emergency physicians, rehabilitation specialists, pharmacists, stroke survivors, and edu-cation experts. This interprofessional approach ensures that the perspectives and nuances of all relevant health disciplines are considered in the development of the recommendations, and mitigates the risk of potential or real conflicts of interest from individual members. Other experts outside the writing group were consulted for very specific issues such as sleep apnea.
A systematic literature search was conducted to identify research evidence for each topic area addressed in the prevention of stroke module. All literature searches are conducted by individuals with expertise performing systematic literature reviews that are not directly involved in active research or the writing group to ensure objective selection of evidence. Literature searches include set time frames, which overlap the previous search time frame by six-months to ensure high catchment of key articles within that time frame.
The writing group was provided with comprehensive evidence tables that include summaries of all high-quality evidence identified through the literature searches. The writing group discusses and debates the value of the evidence and through consensus develops a final set of proposed recommendations. Through their discussions, additional research may be identified and added to the evidence tables if consensus on the value of the research is achieved. All recommendations are assigned a level of evidence ranging from A to C, according to the criteria defined in Table 1 . When developing and including 'C-Level' recommendations, consensus is obtained among the writing group and validated through the internal and external review process. This level of evidence is used cautiously, and only when there is a lack of stronger evidence for topics considered important system drivers for stroke care (e.g. transport using ambulance services or some screening practices). Recommendations with this level of evidence may also be made in response to requests from a range of health-care professionals who seek guidance and direction from the experts in the absence of strong evidence on certain topics that are faced on a regular basis.
After completion of the draft update to the recommendations, the prevention module underwent an internal review by the Canadian Stroke Best Practices Advisory Committee, and an external review by 10 experts in stroke prevention who were not involved in any aspects of the guideline development, including two international reviewers. All feedback was reviewed and addressed by the writing group members and the advisory committee to ensure a balanced approach to addressing suggested edits. All recommendations are accompanied by additional supporting information, including a rationale for inclusion of the topics, system implications to ensure the structural elements and resources are available to achieve the recommended levels of care, performance measures to monitor care delivery and patient outcomes, as well as implementation resources and a summary of the evidence to which the recommendations were based. The evidence tables are available as well. This additional supporting information for the recommendations included in this publication can be found at http://www.strokebestpractices.ca/ index.php/prevention-of-stroke/.
For a more detailed description of the methodology on the development and dissemination of the Canadian Stroke Best Practice Recommendations please refer to the Canadian Stroke Best Practice Recommendations Overview and Methodology documentation available on the Canadian stroke best practices Web site at http://www.strokebestpractices.ca/wp-content/uploads/2014/08/ CSBPR2014_Overview_Methodology_ENG.pdf (13) .
Secondary prevention of stroke Canadian Stroke Best Practice Recommendations
This section provides recommendations, with accompanying evidence grades, for secondary prevention of stroke. For more details on the rationale for the recommendations, health system implications, suggested performance measures, implementation resources, and detailed evidence summaries and tables of evidence, please visit http://www.strokebestpractices.ca. All recommendations included in this section have been translated into French, and the French version can be found in Appendix S1. iii. All patients with suspected TIA or ischemic stroke should undergo an ECG to assess baseline cardiac rhythm and to provide information regarding evidence of structural heart disease (i.e. previous myocardial infarction, left ventricular hypertrophy) (Evidence Level C). iv. In cases where the ECG or initial cardiac rhythm (e.g. 24 or 48 h ECG monitoring) does not show atrial fibrillation but a cardioembolic mechanism is suspected, prolonged ECG monitoring is recommended in selected patients for the detection of paroxysmal atrial fibrillation (i.e. older patients with recent embolic stroke of undetermined source who are potential candidates for anticoagulant therapy) (Evidence Level B). v. Echocardiogram may be considered in cases where the stroke mechanism has not been identified (Evidence Level C). vi. Selected patients with clinical evidence of ischemic stroke who are not admitted to hospital should be assessed for functional impairment when appropriate (e.g. cognitive evaluation, screening for depression, screening of fitness to drive, and functional assessments for potential rehabilitation treatment) (Evidence Level B).
Section 2: Lifestyle and risk factor management 2.0 Persons at risk of stroke and patients who have had a stroke should be assessed for vascular disease risk factors and lifestyle management issues (diet, sodium intake, exercise, weight, alcohol intake, and use of oral contraceptives and hormone replacement therapy) (Evidence Level B).
i. They should receive information and counseling about possible strategies to modify their lifestyle and risk factors (Evidence Level B). ii. Referrals to appropriate specialists should be made where required to provide more comprehensive assessments and structured programs to manage risk factors (Evidence Level B). . Following Canada's Low-Risk Alcohol Drinking Guidelines is recommended: for women, no more than 10 drinks per week, with no more than 2 drinks per day most days and no more than 3 drinks on any single occasion; for men, no more than 15 drinks per week, with no more than 3 drinks per day most days and no more than 4 drinks on any single occasion (Evidence Level C).
Healthy balanced diet:
Counsel and educate individuals with stroke to eat a diet high in fruits, vegetables, low-fat dairy products, dietary and soluble fibre, whole grains and protein from plant sources and low in saturated and trans fats, low in cholesterol (<200 mg daily for patients at increased vascular risk) and low in sodium, in accordance with Canada's Food Guide (Evidence Level
Oral Contraceptives and Hormone Replacement Therapy:
Individuals with stroke who are taking estrogen-containing oral contraceptives or hormone replacement therapy should have the risks and benefits of these treatments discussed with them (Evidence Level C).
i. Estrogen-containing oral contraceptives or hormone replacement therapy should be discontinued in patients with stroke. Management alternatives should be considered in these patients (Evidence Level B). 2.7 Recreational Drug Use: Individuals with stroke and known recreational drug use should be counseled to discontinue use (Evidence Level C), and should be provided with appropriate support and referrals to services and resources for drug addiction (Evidence Level B).
Section 3: Blood pressure and stroke prevention 3.0 Hypertension is the single most important modifiable risk factor for stroke. Blood pressure should be monitored and managed in all persons at risk for stroke (Evidence Level A).
Blood pressure assessment
All persons at risk of stroke should have their blood pressure measured routinely, ideally at each health-care encounter, but no less than once annually (Evidence Level C).
i. Proper standardized techniques should be followed for initial and subsequent blood pressure measurement including office, home, and community testing (Evidence Level B) as outlined by the Canadian Hypertension Education Program.
ii. Patients found to have elevated blood pressure (systolic greater than 130 mmHg and/or diastolic greater than 85 mmHg) should undergo thorough assessment for the diagnosis of hypertension (Evidence Level C). a. A specific follow-up visit should be scheduled and completed for the assessment and diagnosis of hypertension following an initial elevated blood pressure measurement (Evidence Level C). b. The specific visit for assessment of hypertension should include three measurements and be conducted in accordance with the current guidelines of the Canadian Hypertension Education Program (Evidence Level C). iii. Patients with refractory hypertension should have comprehensive investigations for secondary causes of hypertension (Evidence Level B).
iv. Patients with hypertension or at risk for hypertension (in prehypertension state or other risk factors) should receive aggressive risk factor modification counseling and interventions (Evidence Level B). Refer to the recommendations in section 2 on Lifestyle Management for additional information.
Blood pressure management
Blood pressure should be managed in all patients to reach optimal control as follows:
i. For patients who have had a stroke or TIA, blood pressure lowering treatment is recommended to achieve a target of consistently lower than 140/90 mmHg (Evidence Level B).
ii. In patients with diabetes, blood pressure-lowering treatment is recommended for the prevention of first or recurrent stroke to attain systolic blood pressure targets consistently lower than 130 mmHg (Evidence Level C) and Guidelines
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diastolic blood pressure targets consistently lower than 80 mmHg (Evidence Level B). iii. In patients with nondiabetic chronic kidney disease, blood pressure lowering treatment is recommended for the prevention of first or recurrent stroke to attain a blood pressure consistently lower than 140/90 mmHg (Evidence Level C).
iv. For recommendations on specific agents and sequence of agents for the secondary prevention of ischemic stroke, refer to the Canadian Hypertension Education Program treatment guidelines (14) . v. Randomized controlled trials have not defined the optimal time to initiate blood pressure-lowering therapy after stroke or TIA. Blood pressure-lowering treatment should be initiated or modified before discharge from hospital (Evidence Level B). vi. Patients who are not started on hypertensive therapy in acute care should have arrangements made for follow-up with primary care for ongoing evaluation and management (Evidence Level C). vii. For children, blood pressure should be targeted below the 95 percentile for age, height and gender (Evidence Level B). 
Lipid assessment
i. Fasting lipid levels [total cholesterol, total triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol] should be measured on all patients presenting with stroke or TIA (Evidence Level B).
Lipid management
i. Patients with ischemic stroke or TIA should be managed with aggressive therapeutic lifestyle changes to lower lipid levels, including dietary modification, as part of a comprehensive approach to lower risk of first or recurrent stroke (Evidence Level B).
ii. A statin should be prescribed as secondary prevention to most patients who have had an ischemic stroke or TIA in order to achieve an LDL cholesterol of less than 2·0 mmol/l, or a 50% reduction in LDL cholesterol from baseline (Evidence Level B) (15) .
iii. Statin therapy is not indicated for prevention of intracerebral hemorrhage (Evidence Level B). 
Diabetes assessment
i. Patients with ischemic stroke or TIA should be screened for diabetes with a fasting plasma glucose, glycated hemoglobin (A1C) or 75 g oral glucose tolerance test soon after admission to hospital (Evidence Level C) (16) .
ii. For patients with diabetes and either ischemic stroke or TIA, glycated hemoglobin (A1C) should be measured as part of a comprehensive stroke assessment (Evidence Level B).
Diabetes management
i. Glycemic targets must be individualized; however, therapy in most patients with type 1 or type 2 diabetes and stroke or TIA should be treated to achieve a glycated hemoglobin (A1C) level ≤7·0% to reduce the risk of microvascular complications (Evidence Level A) and, in individuals with type 1 diabetes, macrovascular complications (Evidence Level C).
ii. To achieve an A1C ≤7·0%, patients with type 1 or type 2 diabetes should aim for a fasting plasma glucose or preprandial plasma glucose target of 4·0 to 7·0 mmol/l (Evidence Level B).
iii. The two-hour postprandial plasma glucose target is 5·0 to 10·0 mmol/l (Evidence Level B). If A1C targets cannot be achieved with a postprandial target of 5·0 to 10·0 mmol/l, further postprandial blood glucose lowering, to 5·0 to 8·0 mmol/l, can be considered (Evidence Level C). iv. Adults with diabetes and ischemic stroke are at high risk of further vascular events and should also be treated with a statin to achieve a low-density lipoprotein cholesterol ii. Short-term concurrent use of ASA and clopidogrel (up to 90 days) has not shown an increased risk of bleeding (Evidence Level A); however, longer-term use is not recommended for secondary stroke prevention, unless there is an alternate indication (e.g. drug-eluting stent requiring dual antiplatelet therapy), due to an increased risk of bleeding and mortality (Evidence Level A).
iii. The combination of ASA (81 mg) and clopidogrel 75 mg is still of uncertain benefit in the Canadian setting for early prevention of recurrent stroke when used within 90 days, and should not be routinely used in all patients (Evidence Level C v. In children with stroke the usual maintenance dosage of ASA is 1 to 5 mg/kg per day for the prevention of recurrent stroke (Evidence Level B). The usual maximum dose is 81 mg/day. vi. The evidence for clopidogrel use in children is sparse at this time. Clopidogrel may be considered an alternative for adolescents at a dose of 1 mg/kg/day up to a maximum of 75 mg/day. Younger children may have higher anti-platelet effects of clopidogrel, and the suggested doses should be considered within the range of 0·2-0·5 mg/kg/day (Evidence Level C).
Refer to Prevention of Stroke section 7 on Stroke and Atrial Fibrillation for additional recommendations on anticoagulant therapy.
Section 7: Anticoagulation for individuals with stroke and atrial fibrillation 7.1 Detection of Atrial Fibrillation i. All patients with suspected TIA or ischemic stroke should undergo a 12-lead ECG to assess baseline cardiac rhythm and identify atrial fibrillation or flutter, and to provide information regarding evidence of structural heart disease (i.e. previous myocardial infarction, left ventricular hypertrophy) (Evidence Level C).
ii. In cases where the ECG or initial cardiac rhythm monitoring (e.g. 24 or 48 h ECG monitoring) does not show atrial fibrillation but a cardioembolic mechanism is suspected, prolonged ECG monitoring is recommended in selected patients for detection of paroxysmal atrial fibrillation (Evidence Level B) (17).
Prevention of recurrent stroke in patients with nonvalvular atrial fibrillation
i. Patients with TIA or ischemic stroke and atrial fibrillation should receive oral anticoagulation (Evidence Level A).
a. In most patients, direct oral anticoagulants (DOAC) such as apixaban, dabigatran, rivaroxaban, or edoxaban (when available in Canada), should be prescribed in preference over warfarin (Evidence Level B). b. When selecting oral anticoagulants, patient-specific criteria should be considered (Evidence level C). Refer to table 7 for additional information on anticoagulant medications, available at www.strokebestpractices.ca. ii. The time to start oral anticoagulation following TIA or ischemic stroke is unclear and therapy should be started as soon as it is thought to be safe for the patient (Evidence Level C). iii. For patients with acute ischemic stroke and atrial fibrillation, routine use of bridging with heparin is not recommended (Evidence Level B). Physicians should use antiplatelet agents until the patient is anticoagulated (Evidence Level C). Refer to Prevention of Stroke section 6 on Antiplatelet Therapy for Ischemic Stroke and TIA for additional recommendations on antithrombotic therapy.
Enhancing anticoagulation therapy and minimizing bleeding complications
i. Medication adherence is important for patients on all oral anticoagulants. For patients with atrial fibrillation that are taking warfarin, careful dosing and consistent international normalized ratio monitoring is recommended to minimize adverse events; warfarin efficacy is dependent on maintaining therapeutic international normalized ratio control, and declines significantly when the international normalized ratio falls below 2·0 (Evidence Level A).
ii. For patients prescribed apixaban, dabigatran, rivaroxaban, or edoxaban (when available in Canada), renal function should be routinely monitored, and measured at least once annually or when there is a change in health status (Evidence Level C). Dose adjustments may be required based on changes in renal function if detected.
iii. Concomitant antiplatelet therapy with oral anticoagulation is not recommended in patients with atrial fibrillation unless there is a specific medical indication (Evidence Level B). i. In all health-care settings along the stroke continuum (inpatient, ambulatory, and community), patient smoking status should be identified, assessed and documented (Evidence Level A).
ii. Provide unambiguous, nonjudgmental, and patientspecific advice regarding the importance of cessation to all smokers (Evidence Level B) and others who reside with the patient.
iii. Offer assistance with the initiation of a smoking cessation attempt -either directly or through referral to appropriate resources (Evidence Level A).
iv. People who are not ready to quit should be offered a motivational intervention to help enhance their readiness to quit (Evidence Level B).
v. A combination of pharmacological therapy and behavioral therapy should be considered in all smoking cessation programs and interventions (Evidence Level A).
vi. The three classes of pharmacological agents that should be considered as first-line therapy for smoking cessation are nicotine replacement therapy, bupropion, and varenicline (Evidence Level A).
a. The choice of appropriate pharmacotherapy should take into account the patient's medical stability, clinical needs, other medical factors, and patient preferences (Evidence Level C). vii. For admitted stroke patients who are current smokers, protocols should be in place to manage nicotine withdrawal during hospitalization (Evidence Level B). viii. There is a lack of clear evidence regarding the timing to initiate nicotine withdrawal/replacement therapy in patients following a stroke. Expert opinion suggests this should begin as soon as possible (Evidence Level C).
ix. Interdisciplinary team members should counsel patients, family members, and caregivers about the harmful effects of exposure to second-hand smoke (Evidence Level B).
Section 10: Sleep apnea and stroke 10.0 Obstructive sleep apnea (OSA) should be considered a risk factor for stroke and has also been shown to be present in many patients following a stroke (Evidence Level B). Preventative strategies should be in place for people with OSA or in stroke patients who develop sleep disturbances following a stroke (Evidence Level B).
Screening and assessment for sleep apnea
i. Patients who have experienced a stroke or TIA should be screened for the presence of sleep apnea symptoms (Evidence level B).
a. Screening for the presence of sleep apnea should occur during follow-up visits (Evidence level C), using a validated sleep apnea screening tool. ii. Patients with symptoms suggestive of sleep apnea on initial screening should be referred to a sleep specialist (Evidence level C).
Management of OSA in patients with stroke
Stroke prevention strategies, including specific targeted management strategies for sleep apnea should be initiated for patients with confirmed sleep apnea post stroke or TIA, based on objective clinical assessment and investigations (Evidence Level B).
i. (20) .
Pediatric considerations:
There is no direct evidence available to demonstrate a connection in children regarding sleep apnea and stroke. However, it is recommended that children with stroke be screened for signs and symptoms suggesting sleep apnea (Evidence Level C), or conditions predisposing them to sleep apnea, such as obesity, sickle cell disease, severe strokes, or structural airway problems (e.g. enlarged tonsils) (Evidence Level C).
i. Any child with suspected sleep apnea should be referred to a pediatric sleep specialist (Evidence Level C). ii. Stroke presumably related to a Patent Foramen Ovale should be managed following the stroke prevention recommendations included in this Heart and Stroke Foundation (HSF) Secondary Prevention of Stroke Module (Evidence Level C).
iii. Aortic arch atheroma should be managed following the stroke prevention recommendations included in this HSF Secondary Prevention of Stroke Module (Evidence Level C).
Summary
The Canadian Stroke Best Practice Recommendations provide a common set of guiding principles for stroke care delivery and describe the infrastructure necessary at a system level, and the clinical protocols and processes that are needed to achieve and enhance integrated, high-quality, and efficient stroke services. Through the innovations embodied within the stroke best practices, these guidelines contribute to health system reform in Canada and internationally. The Canadian Stroke Best Practice Recommendations are developed and presented within a continuous improvement model and are written for health system planners, funders, administrators, and health-care professionals, all of whom have important roles in the optimization of stroke prevention and care and who are accountable for results. A strong stroke research literature base is drawn upon to guide the optimization of stroke prevention and care delivery. Several implementation tools are provided to facilitate uptake into practice (available at www.strokebestpractices.ca) and are used in combination with active professional development programs. By monitoring performance, the impact of adherence to best practices is assessed and results then used to direct ongoing improvement. Recent stroke quality monitoring activities have compelling results, which continue to support the value of adopting evidence-based best practices in organizing and delivering stroke care in Canada.
The Canadian Stroke Best Practice Recommendations prevention guidelines continue to be a work in progress and are regularly updated every two-to three-years in order to integrate newly released data to help maximize patient outcomes from this disabling disease.
